Literature DB >> 11848292

In-vitro distribution of terbinafine in rat and human blood.

Mahboubeh Hosseini Yeganeh1, Andrew J McLachlan.   

Abstract

The association of drugs with plasma lipoproteins has the potential to influence drug action and disposition. In this study, the uptake and distribution of the lipophilic antifungal drug, terbinafine, was investigated in rat and human blood and plasma. Fresh plasma was incubated with terbinafine (200-1000 ng mL(-1)), then subjected to vertical spin density gradient ultracentrifugation to separate protein fractions. The concentrations of terbinafine in each fraction was determined using a validated reversed-phase HPLC method. The association of terbinafine with very-low-density lipoproteins (15.5 +/- 7.1% of total concentration) in human plasma was significantly lower than that associated with fractions containing soluble proteins (28.0 +/- 6.2%), high- (26.8 +/- 7.7%) and low-density lipoproteins (31.6 +/- 4.6%). In rats terbinafine was found to be distributed evenly through plasma protein fractions. The association of terbinafine in lipoproteins was independent of concentration (over the range 200-1,000 ng mL(-1)) and species. The distribution of terbinafine was examined in human and rat blood and the blood-to-plasma ratio of terbinafine was 0.70+0.09 and 1.01 +/- 0.20, respectively, indicating higher association of terbinafine with plasma components than erythrocytes in humans. This study suggests that in humans and rats, terbinafine associates with a number of plasma proteins independently of terbinafine concentration. Alteration in plasma lipoprotein concentrations are therefore likely to influence terbinafine binding in blood and distribution in the body.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11848292     DOI: 10.1211/0022357021778312

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

Review 1.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Physiologically based pharmacokinetic model for terbinafine in rats and humans.

Authors:  Mahboubeh Hosseini-Yeganeh; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  Expeditious Enyne Construction from Alkynes via Oxidative Pd(II) Catalyzed Heck-Type Coupling.

Authors:  Victor Hadi; Kyung Soo Yoo; Min Jeong; Kyung Woon Jung
Journal:  Tetrahedron Lett       Date:  2009-05-20       Impact factor: 2.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.